Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
298 hedge funds and large institutions have $4.81B invested in Amicus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 111 increasing their positions, 89 reducing their positions, and 80 closing their positions.
36% more call options, than puts
Call options by funds: $9.21M | Put options by funds: $6.76M
25% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 89
23% more funds holding in top 10
Funds holding in top 10: 13 → 16 (+3)
5% more capital invested
Capital invested by funds: $4.57B → $4.81B (+$235M)
1.84% more ownership
Funds ownership: 104.07% → 105.92% (+1.8%)
10% less funds holding
Funds holding: 332 → 298 (-34)
35% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 80
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$166M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$159M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$144M |
| 4 |
Goldman Sachs
New York
|
+$77.6M |
| 5 |
Millennium Management
New York
|
+$70.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$153M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$151M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$92.7M |
| 4 |
PA
Perceptive Advisors
New York
|
-$90.7M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$74.2M |
FOLD Hedge Fund Activity: Q1 2026 in Review
298 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2026, worth a combined $4.81B — up 5.1% from $4.57B a quarter earlier.
Sellers outnumbered buyers: 80 funds closed out of FOLD and 52 opened new positions — a net loss of 28 holders — while 89 trimmed existing stakes and 111 added.
The largest buyer was Fidelity International, adding an estimated $166M. The largest seller was Bellevue Group, exiting entirely with an estimated $153M sold.
- 298 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2026, down from 332 in Q4 2025.
- Funds reported $4.81B of Amicus Therapeutics stock for Q1 2026, up 5.1% quarter-over-quarter.
- 52 funds opened new Amicus Therapeutics positions in Q1 2026 and 80 closed out, a net change of -28 holders.
- The largest Amicus Therapeutics buyer in Q1 2026 was Fidelity International, an estimated $166M added.
- The largest Amicus Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2026.